SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wen, Y.-J. Articles by Yi, Q. Search for Related Content PubMed PubMed Citation Articles by Wen, Y.-J. Articles by Yi, Q. Related Collections Immunobiology Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 May 2002, Vol. 99, No. 9, pp. 3280-3285 IMMUNOBIOLOGY Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy Yue-Jin Wen, Rui Min, Guido Tricot, Bart Barlogie, and Qing Yi From the Myeloma and Transplantation Research Center, University of Arkansas for Medical Science, Little Rock. The idiotype protein, secreted by myeloma plasma cells, is a tumor-specific but weak antigen. Idiotype-based immunotherapy has been explored in myeloma patients with disappointing results. It is conceivable that myeloma cells contain a multitude of tumor antigens that can more effectively stimulate antitumor T cells. To explore the possibility of using whole myeloma cells as a source of tumor antigens for immunotherapy, the current study was undertaken to generate and examine the function of myeloma-specific cytotoxic T lymphocytes (CTLs) by using dendritic cells (DCs) pulsed with myeloma cell lysates as stimulating cells. After repeated stimulation, specific CTL lines, containing CD4+ and CD8+ T cells, were generated from myeloma patients. Our results show that these T cells not only recognized and lysed autologous myeloma protein-pulsed DCs, they also killed autologous primary myeloma cells. Occasionally, CTLs responded to autologous idiotype-pulsed DCs and to allogeneic primary myeloma cells. No cytolytic activity, however, was detected against autologous lymphocytes including B cells, suggesting that the T cells acted specifically against myeloma cells. Cytotoxicity against target cells was major histocompatibility complex class 1 and, to a lesser extent, class 2 restricted and was dependent mainly on the perforin-mediated pathway. CTLs secreted predominantly interferon- and tumor necrosis factor- on antigenic stimulation, indicating a type 1 T-cell subset. These findings represent the first demonstration that tumor cell lysate-primed CTLs kill only myeloma cells, not autologous lymphocytes. This provides a rationale for myeloma cell-based immunotherapy in multiple myeloma. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Hong, J. Qian, J. Yang, H. Li, L. W. Kwak, and Q. Yi Roles of Idiotype-Specific T Cells in Myeloma Cell Growth and Survival: Th1 and CTL Cells Are Tumoricidal while Th2 Cells Promote Tumor Growth Cancer Res., October 15, 2008; 68(20): 8456 - 8464. [Abstract] [Full Text] [PDF] M. Grube, S. Moritz, E. C. Obermann, K. Rezvani, A. Mackensen, R. Andreesen, and E. Holler CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma Clin. Cancer Res., February 1, 2007; 13(3): 1053 - 1060. [Abstract] [Full Text] [PDF] S. Wang, S. Hong, J. Yang, J. Qian, X. Zhang, E. Shpall, L. W. Kwak, and Q. Yi Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells Blood, December 15, 2006; 108(13): 4071 - 4077. [Abstract] [Full Text] [PDF] S. Wang, J. Yang, J. Qian, M. Wezeman, L. W. Kwak, and Q. Yi Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma Blood, March 15, 2006; 107(6): 2432 - 2439. [Abstract] [Full Text] [PDF] Y. Motomura, S. Senju, T. Nakatsura, H. Matsuyoshi, S. Hirata, M. Monji, H. Komori, D. Fukuma, H. Baba, and Y. Nishimura Embryonic Stem Cell-Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10 Cancer Res., February 15, 2006; 66(4): 2414 - 2422. [Abstract] [Full Text] [PDF] A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma Blood, November 15, 2005; 106(10): 3538 - 3545. [Abstract] [Full Text] [PDF] A. Geffroy-Luseau, A. Moreau-Aubry, R. Bataille, and C. Pellat-Deceunynck Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells Int. Immunol., September 1, 2005; 17(9): 1193 - 1200. [Abstract] [Full Text] [PDF] S. B. Rew, K. Peggs, I. Sanjuan, A. R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K. L. Yong Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24 Clin. Cancer Res., May 1, 2005; 11(9): 3377 - 3384. [Abstract] [Full Text] [PDF] J. Bae, J. A. Martinson, and H. G. Klingemann Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies Clin. Cancer Res., February 15, 2005; 11(4): 1629 - 1638. [Abstract] [Full Text] [PDF] B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF] M. V. Dhodapkar, J. Krasovsky, K. Osman, and M. D. Geller Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy J. Exp. Med., December 1, 2003; 198(11): 1753 - 1757. [Abstract] [Full Text] [PDF] M. F. Kircher, J. R. Allport, E. E. Graves, V. Love, L. Josephson, A. H. Lichtman, and R. Weissleder In Vivo High Resolution Three-Dimensional Imaging of Antigen-Specific Cytotoxic T-Lymphocyte Trafficking to Tumors Cancer Res., October 15, 2003; 63(20): 6838 - 6846. [Abstract] [Full Text] [PDF] W. J. M. Mackus, F. N. J. Frakking, A. Grummels, L. E. Gamadia, G. J. de Bree, D. Hamann, R. A. W. van Lier, and M. H. J. van Oers Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia Blood, August 1, 2003; 102(3): 1057 - 1063. [Abstract] [Full Text] [PDF] L. Hansson, H. Rabbani, J. Fagerberg, A. Osterborg, and H. Mellstedt T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma Blood, June 15, 2003; 101(12): 4930 - 4936. [Abstract] [Full Text] [PDF] M. R. Parkhurst, C. DePan, J. P. Riley, S. A. Rosenberg, and S. Shu Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules J. Immunol., May 15, 2003; 170(10): 5317 - 5325. [Abstract] [Full Text] [PDF] E. Chun, J. Lee, H. S. Cheong, and K.-Y. Lee Tumor Eradication by Hepatitis B Virus X Antigen-Specific CD8+ T Cells in Xenografted Nude Mice J. Immunol., February 1, 2003; 170(3): 1183 - 1190. [Abstract] [Full Text] [PDF] E. Gatza and C. Y. Okada Tumor Cell Lysate-Pulsed Dendritic Cells Are More Effective Than TCR Id Protein Vaccines for Active Immunotherapy of T Cell Lymphoma J. Immunol., November 1, 2002; 169(9): 5227 - 5235. [Abstract] [Full Text] [PDF] M. V. Dhodapkar, J. Krasovsky, and K. Olson T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells PNAS, October 1, 2002; 99(20): 13009 - 13013. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020